A growing number of employers and health plans, including the University of Texas system, Ascension, and the North Carolina state health plan, have eliminated coverage of anti-obesity medications, citing skyrocketing costs.10 Most recently, one of the largest public universities in the United States issued a new coverage policy on GLP-1 agonists for their employees, limiting their coverage to only up to 24 months. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.